Overview

Surufatinib Combined With Serplulimab Plus Chemotherapy in the Treatment of Extensive-stage Small Cell Lung Cancer

Status:
Not yet recruiting

Trial end date:
2026-06-01

Target enrollment:

Participant gender:

Summary

To evaluates the effectiveness and safety of Surufatinib combined with Serplulimab plus chemotherapy for the first-line treatment of ES-SCLC, and maintenance therapy are Surufatinib combined with Serplulimab

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Fujian Cancer Hospital

Collaborators:

Hunan Cancer Hospital
Wuhan TongJi Hospital

Treatments:

Carboplatin
Etoposide